Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta
Trial details
- Registry ID
- NCT06636071
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as BPS804; UX143
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Setrusumab in Pediatric Japanese Subjects With Osteogenesis ImperfectaNCT06636071 | RARE | Phase 3 | Active not recruiting | 2027-01Estimated |
| A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804NCT03118570 | RARE | Phase 2 | Completed | 2019-10-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |